Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients

European Journal of Cancer

Volumn 41, Issue 3, 2005, Pages 386-392

  Smit, Léonie H M ^a   Korse, Catharina M ^a   Hart, Augustinus A M ^a   Bonfrer, Johannes M G ^a   Haanen, John B A G ^a   Kerst, J Martijn ^a   Nieweg, Omgo E ^a   De Gast, Gijsbert C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Lactate dehydrogenase; Melanoma; Metastases; S 100 protein; Survival

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PLASMA PROTEIN; PROTEIN S100B; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; S100 PROTEINS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 13244290107     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.10.019     Document Type: Article

References (22)

1. C.M. Balch, A.C. Buzaid, and S.J. Soong Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 2001 3635 3648
2. M. Deichmann, A. Benner, and M. Bock S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma J Clin Oncol 17 1999 1891 1896
3. M.N. Sirott, D.F. Bajorin, and G.Y. Wong Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis Cancer 72 1993 3091 3098
4. J.M. Bonfrer, C.M. Korse, and O.E. Nieweg The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma Br J Cancer 77 1998 2210 2214
5. A. Hauschild, J. Michaelsen, and W. Brenner Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients Melanoma Res 9 1999 155 161
6. E.S. Schultz, T.L. Diepgen, and P. Von Den Driesch Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma Br J Dermatol 138 1998 426 430
7. A.P. Hamberg, C.M. Korse, and J.M. Bonfrer Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma Melanoma Res 13 2003 45 49
8. A. Hauschild, G. Engel, and W. Brenner Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy Br J Dermatol 140 1999 1065 1071
9. G.C. de Gast, J.M.G. Bonfrer, and J.B.A.G. Haanen Low distant relapse rate following neo-adjuvant and adjuvant chemo-immunotherapy and surgical resection for stage III B/C melanoma is related to serum S100b J Clin Oncol ASCO Proc 22 2003 2908
10. G.C. de Gast, D. Batchelor, and M.J. Kersten Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma Br J Cancer 88 2003 175 180
11. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
12. F.E. Harrell Regression modeling strategies with applications to linear models, logistic regression and survival analysis 2001 Springer verlag New York p. 23-24
13. T.K. Eigentler, U.M. Caroli, and P. Radny Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials Lancet Oncol 4 2003 748 759
14. V.M. Klimek, J.D. Wolchok, and P.B. Chapman Systemic chemotherapy Clin Plast Surg 27 2000 451 456
15. U. Keilholz, S.H. Goey, and C.J. Punt Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group J Clin Oncol 15 1997 2579 2588
16. L.G. Feun, J. Gutterman, and M.A. Burgess The natural history of resectable metastatic melanoma (stage IVA melanoma) Cancer 50 1982 1656 1663
17. W.S. Fletcher, R.F. Pommier, and S. Lum Surgical treatment of metastatic melanoma Am J Surg 175 1998 413 417
18. E.C. Hsueh, R. Essner, and L.J. Foshag Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine J Clin Oncol 20 2002 4549 4554
19. C.P. Karakousis, A. Velez, and D.L. Driscoll Metastasectomy in malignant melanoma Surgery 115 1994 295 302
20. T.K. Overett, and M.H. Shiu Surgical treatment of distant metastatic melanoma. Indications and results Cancer 56 1985 1222 1230
21. I.L. Wornom III, J.W. Smith, and S.J. Soong Surgery as palliative treatment for distant metastases of melanoma Ann Surg 204 1986 181 185
22. J.D. De Vries, O.E. Nieweg, and R.F. Uren Positron emission tomography J.F. Thompson D.L. Morton B.B. Kroon Textbook of Melanoma 2004 Martin Dunitz London 477 481